Skip to main content

RxGen Gets $1.1M SBIR Grant to Study Genomic Markers of Parkinson s Disease

NEW YORK, Dec. 8 (GenomeWeb News) - RxGen has received a $1.1 million Fast Track SBIR grant to identify genomic markers of Parkinson's disease.


The New Haven, Conn.-based firm will use its PrimaTox predictive toxicology technology program to study toxins such as rotenone, tetrahydroisoquinolone, dithiocarbamate, and Paraquat, which have been implicated as possible environmental causes of Parkinson's disease.


RxGen said it would profile in vivo brain RNA expression patterns following exposure to the toxins in an attempt to uncover critical pathways of injury and neuroprotection specific to dopaminergic neurons.

The Scan

Call to Look Again

More than a dozen researchers penned a letter in Science saying a previous investigation into the origin of SARS-CoV-2 did not give theories equal consideration.

Not Always Trusted

In a new poll, slightly more than half of US adults have a great deal or quite a lot of trust in the Centers for Disease Control and Prevention, the Hill reports.

Identified Decades Later

A genetic genealogy approach has identified "Christy Crystal Creek," the New York Times reports.

Science Papers Report on Splicing Enhancer, Point of Care Test for Sexual Transmitted Disease

In Science this week: a novel RNA structural element that acts as a splicing enhancer, and more.